Cytokine Signalling Forum


Romatoid artritli hastalarda tocilizumab ya da adalimumab ile tedaviden sonra lipid ve lipid ile ilişkili kardovasküler risk belirteçlerindeki değişimin karşılaştırılması

Gabay C, McInnes IB, Kavanaugh A, Tuckwell K, Klearman M, Pulley J, Sattar N. - Ann Rheum Dis. 2015;0:1-7. doi:10.1136/annrheumdis-2015-207872 [Epub ahead of print]

RA patients have increased risk of CVD compared with the general population that is not fully explained by traditional risk factors. This is a post-hoc analysis of data from a clinical trial that compared IL-6 and TNF-α signaling inhibition to compare changes in lipids and lipid-associated CV risk markers in 324 patients treated with TCZ IV q4w or ADA SC q2w for 24 weeks. HDL-SAA and sPLA2 IIA is also measured in an additional subpopulation of 87 and 97 TCZ and ADA patients, respectively.

Greater increases in LDL-C, HDL-C, TC, triglycerides, and TC:HDL ratio were seen with TCZ from baseline to 8 weeks. HDL-SAA, sPLA2 IAA, and Lp(a) were shown to decrease more with TCZ than ADA. Similar results were observed between ACR and EULAR responders and non-responders.

Lipid change effects of IL-6 and TNF-α inhibition do not have synonymous manifestations in net impact on lipids and lipoproteins. The clinical significance of this is unclear and requires further study.

Keywords: IL-6, Tocilizumab, Cardiovascular

Access original article via Pubmed

Upload date: December 2015

Translated by: Şafak Mirioğlu

Article image